IceCure (ICCM) COO Levav Shay Receives 141,483 RSU Award

What Happened

• Levav Shay, Chief Operating Officer of IceCure Medical Ltd. (ICCM), received an award of 141,483 restricted share units (RSUs) on August 14, 2026. The award was granted at a $0.00 per-share acquisition price (typical for RSU grants), so no cash changed hands and the immediate transaction value is $0.
• This grant is in addition to prior RSU grants (2,727 on July 2, 2024; 1,447 on November 5, 2025; and 646 on March 16, 2026). Adjusted for the issuer’s 1-for-30 reverse stock split, the total RSUs from all listed grants equal 146,303 RSUs, the vast majority of which remain unvested as of August 13, 2026.

Key Details

• Transaction date: August 14, 2026; reported on Form 4 filed August 17, 2026 (timely; Form 4 generally due within 2 business days).
• Price: $0.00 per RSU (grant). Reported immediate value: $0.
• Shares/units awarded: 141,483 RSUs (new grant). Aggregate RSUs from disclosed grants: 146,303 RSUs.
• Vesting (not yet vested except noted): 25% of the 141,483 RSUs vest on August 11, 2027; remaining 75% vest in twelve equal quarterly installments (6.25% each) thereafter. Prior grants: 25% of the July 2, 2024 grant vested July 29, 2026; remaining prior-grant tranches vest quarterly at 6.25% increments.
• Footnote: earlier grants (2024–2026) adjusted for the issuer’s 1-for-30 reverse split.
• Shares owned after transaction: the filing does not report total shares beneficially owned beyond the RSU amounts disclosed; disclosed RSU total = 146,303.

Context

• RSUs are awards that convert into shares only upon vesting; they do not represent immediately tradable shares and are not a cash purchase or sale. Such grants are standard executive compensation and do not by themselves signal a buy or sell decision.